Schott Pharma AG KGaAFRA:1SX -0.98%67 EBITDA Margin % is 26.70% as of Mar. 2026, which is 0% below its 10-year median of 26.80. GuruFocus rates FRA:1SX with a GF Score™ of 67/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 89.47% on this metric.
Schott Pharma AG KGaA (FRA:1SX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Schott Pharma AG KGaA EBITDA Margin % Related Terms
Schott Pharma AG KGaA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1SX vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (FRA:1SX) has a EBITDA Margin % of 26.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Schott Pharma AG KGaA and its competitors. This is near median its historical median of 26.80. Over the past decade, Schott Pharma AG KGaA's EBITDA Margin % has ranged from 22.41 to 29.12. According to the industry distribution chart, Schott Pharma AG KGaA ranks #86 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 10.5%.
Is Schott Pharma AG KGaA's EBITDA Margin % too high?
Schott Pharma AG KGaA's current EBITDA Margin % of 26.70% is near median its 10-year median of 26.80. Over the past 10 years, this metric has ranged from a low of 22.41 to a high of 29.12. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Schott Pharma AG KGaA's value of 26.70% is 258.9% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #86 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #86 out of 817 companies for EBITDA Margin %. This places Schott Pharma AG KGaA in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.44. Schott Pharma AG KGaA's value of 26.70% is 258.9% above this benchmark. Historically, Schott Pharma AG KGaA's own EBITDA Margin % has ranged from 22.41 to 29.12 over the past decade. While the company's 10-year median is 26.80 vs. the industry median of 7.44, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current EBITDA Margin % of 26.70% is 258.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current EBITDA Margin % is 26.70%, which is near median its own 10-year median of 26.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current EBITDA Margin % of 26.70%. The stock's GF Value™ is €6.49, compared to a current price of €4.04 — trading 37.8% below its estimated fair value. The current EBITDA Margin % is 26.70%, which is near median its 10-year median of 26.80 and 258.9% above the Medical Devices & Instruments industry median of 7.44. Schott Pharma AG KGaA's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current EBITDA Margin % is 26.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €4.04 is trading 37.8% below its estimated GF Value™ of €6.49.
Key valuation signals for FRA:1SX:
EBITDA Margin %: 26.70% (near median its 10-year median of 26.80)
GF Value™: €6.49 vs. price of €4.04 (37.8% below fair value)
Industry Position: 258.9% above the Medical Devices & Instruments median (#86 of 817)
No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
67GF Score
Get the complete analysis for FRA:1SX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SX has been successfully added to your 
